Wave Life Sciences Ltd. (NASDAQ: WVE) is among the 13 Best Healthcare Stocks to Buy Under $10. Analyst Joseph Schwartz of Leerink Partners reiterated a Buy rating on WVE with a price target of $24.00 on July 4. The company shows promising developments in RNA editing, particularly in treating AATD, with positive initial human data for the WVE-006 compound. The breakthrough marks a significant milestone for Wave Life Sciences Ltd. and sets a precedent in the RNA editing domain. Analyst Schwartz expects upcoming data readouts to have positive outcomes, with a potential dose-dependent rise in efficacy. The company’s potential to exceed the established threshold for AAT protein levels could significantly boost the stock’s value. Wave Life Sciences Ltd. is a clinical-stage biotechnology company that develops and commercializes RNA medicines through its PRISM platform, focusing on treating prevalent and rare disorders. While Wave Life Sciences Ltd. shows investment potential, some AI stocks offer greater upside potential with less downside risk. For a free report on the best short-term AI stock, visit the provided link.

Read more at Yahoo Finance: Leerink Partners Reiterates a Buy Rating on Wave Life Sciences (WVE), Keeps the PT at $24